Stem Cells in Rapidly Evolving Active Multiple Sclerosis
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind crossover study to study the effect of intravenous
treatment with autologous (derived from the individuals themselves) mesenchymal stem cells
(MSCs) in patients with multiple sclerosis (MS).